Kintor puts hair loss AR antagonist on

China-based Kintor Pharmaceutical Ltd (9939.HK) is set to market its AR antagonist KX-826 (pyrilutamide), a treatment for androgenetic alopecia (male pattern baldness), on Chinese e-commerce giant’s online drug retail portal Kintor will also recruit more than 100 salespeople to support sales of the product.

Kintor is a clinical-stage biotech covering research and development, manufacturing and sales of innovative small molecules against prostate, breast, and liver cancers. Another lead drug candidate, GT0918 (proxalutamide), is subject to a Phase III clinical study in metastatic castration-resistant prostate cancer (mCRPC) in China, and a Phase II study in breast cancer in the US. The company completed an initial public offering (IPO) of 92,347,500 shares to the Hong Kong Stock Exchange (HKSE) in May this year, raising HKD 1.86 billion (USD 240 million).


Related news
China-based Suzhou Kintor Pharmaceuticals has raised USD 45 million, following RMB 288 million (USD 40.8 million) from a Series C round in February 2018 previously reported by GBI.
Bloomberg reports that two more China-based drug developers, Suzhou Kintor Pharmaceuticals Inc., and Frontier Biotechnologies, are in the early stages of preparing formal applications to hold initial public offerings (IPOs) on the Stock Exchange of Hong Kong (SEHK)’s Main Board.
U.S.-based precision medicine company Predicine formed a global strategic partnership with Suzhou Kintor Pharmaceuticals.
China-based Suzhou Kintor Pharmaceuticals Inc., successfully completed a Series C financing round, raising RMB 288 million (USD 44.5 million).
Jiangsu’s provincial Food and Drug Administration bureau issued a notification that a first product has been approved by the China Food and Drug Administration (CFDA) to enter the local marketing authorization holder (MAH) pilot scheme.
  • 1501643558115
  • China
  • Drug
Recent news
According to GBI analysis, Colombia’s National Food and Drug Surveillance Institute (INVIMA) recently approved Pfizer subsidiary Wyeth’s antihemorrhagic BeneFIX (recombinant coagulation factor IX), Pfizer’s human growth hormone analog Somavert (pegvisomant), and Mundipharma’s antineoplastic Difolta (pralatrexate).
Argentina’s Ministry of Health (MoH) this week launched two drug procurement processes.
Mexico’s Congress last week passed an Industrial Innovation Protection Law, which was announced last month.
Paraguay's Ministry of Health (MSPBS) this week launched its Drugs and Medical Supplies National Monitoring System, an online platform that keeps track of health products distribution in the public healthcare system as well as their cost.
Germany-based giant Merck KGaA has opened its M Lab Collaboration Center in Pudong, at the heart of the biomedical sciences and research community in Shanghai.
The cloud summit of World Artificial Intelligence Conference (WAIC) held in Shanghai this year saw China’s technology giant Tencent launch iDrug, its first AI-empowered drug research and development (R&D) platform, designed to galvanize novel drug development via technology. iDrug covers the whole process of pre-clinical development: protein structure screening, virtual screening, molecular design and optimization, and synthetic route planning.
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (688266.SH) announced the go-ahead from the National Medical Products Administration (NMPA) to initiate a clinical study for its donafenib combined with Genor Biopharma Co., Ltd’s programmed death-1 (PD-1) inhibitor genolimzumab in advanced hepatocellular carcinoma (HCC), gastric cancer including gastroesophageal junction adenocarcinoma (GC/GEJ), renal cell carcinoma (RCC), colorectal cancer (CRC), and other advanced solid tumors. Donafenib (CM4307) is a small-molecule oral multi-kinase inhibitor with activity against serine-threonine kinase (Raf/MEK/ERK) signaling, vascular endothelial growth factor receptor (VEGFRs) and platelet-derived growth factor receptor (PDGFR), designed to directly and indirectly inhibit tumor cell proliferation and growth.
Analytics Snapshot

Analytics Snapshot